Clinical trials: Misfolding Disease, Protein
Parkinson Disease, MSA - Multiple System Atrophy
Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease
Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages.
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Lewy Body Dementia (LBD), Neurodegenerative Disease
- Trial name
- EXTRAORDINARY (NCT06846658)
- Where
- 3 sites in Italy
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
AL Amyloidosis
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light…
- Trial name
- NCT05451771
- Testing
- Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- Columbia University
Prion Disease
A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)
This study will test a Regeneron drug called ALN-6457 ("study drug") to see if it can help treat Prion Disease (PrD). In PrD, the prion protein folds into an abnormal shape.
- Trial name
- NCT07832370
- Testing
- ALN-6457
- Volunteers
- 60 people
- Sponsor
- Regeneron Pharmaceuticals
Parkinson's Disease
Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)
The study will investigate the biomarker of a-synuclein aggregate in CSF detected by protein misfolding cyclic amplification (PMCA) and its sensitivity and specificity in diagnosing Parkinson's disease at H-Y stage I and disease…
- Trial name
- NCT04536857
- Testing
- Biomarker assay
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Huashan Hospital
Preeclampsia, CAS
Preeclampsia and Contact Activation
Preeclampsia (PE) affects approximately 5% of all pregnancies with 2,500 cases registered annually in Denmark. PE is characterized by incomplete modelling of the spiral arteries of the uterus, hypertension, inflammation…
- Conditions
- Preeclampsia, CAS, Misfolding Disease, Protein
- Trial name
- NCT04825145
- Testing
- Pregnancy
- Where
- Denmark
- Volunteers
- 234 people
- Sponsor
- University of Southern Denmark